GET DAILY SIGNALSEnovis (ENOV): Analyst Targets Signal +28% Upside from Recent Levels
Key Takeaways
- The central target of $36 is the arithmetic mean of roughly ten current, individually verified analyst price targets, which span a wide $27 to $47 range.
- At a recent price near $28 following third-quarter 2026 results, reaching $36 would require a gain of roughly 28% — a substantial, though not extraordinary, move.
- Sentiment is broadly constructive: most covering analysts rate ENOV a Buy, but nearly every firm lowered its target during 2026, reflecting caution around margins and the eCential Robotics acquisition.
- The strongest supports are mid-single-digit organic revenue growth, reaffirmed full-year 2026 guidance, and a long-term robotics growth strategy.
- The biggest risks are recurring net losses tied to impairments, near-term margin pressure, and unusually wide disagreement among analysts about fair value.
- For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
- You can also explore Trending AI Robots to see how automated strategies are interpreting shifting market conditions.
Understanding the Analyst Consensus on ENOV
Enovis Corporation (ENOV) operates in the medical technology space with Prevention & Recovery and Reconstructive segments. The $36 central target reflects the average of about ten current analyst price targets from identifiable firms and dates. Those estimates range from a cautious $27 at BMO Capital to an optimistic $47 at Citizens JMP, highlighting a meaningful spread in views. Recent examples include Needham at $34 (October 2026), UBS at $44, BTIG at $36, Wells Fargo at $33, Canaccord Genuity at $45, Freedom Capital Markets at $36, and J.P. Morgan at $28 with a Hold rating. Most ratings lean toward Buy, yet the dispersion stands out for the sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Lower target revisions stem largely from the €155 million eCential Robotics acquisition, which adds long-term potential but weighs on near-term margins and cash flow.
Current Position and the Path to $36
ENOV shares traded near $28 in early November 2026, rebounding from the low-to-mid $20s seen through much of the autumn and well above the 52-week low near $16.70. Reaching the $36 mean target would imply roughly 28% upside from that level, a move that would need sustained fundamental progress. The route likely hinges on organic revenue growth in the 4% to 6% range for 2026, margin stabilization, and better conversion of earnings into free cash flow. Management has guided toward roughly 50% free cash flow conversion next year and margin expansion resuming around 2028.
Factors That Could Support the Target
- Reaffirmed guidance: Full-year 2026 revenue of $2.31–$2.37 billion and adjusted EPS of $3.52–$3.73, with organic growth of 4–6%.
- Earnings momentum: Second-quarter 2026 adjusted EPS of $0.90 beat the $0.85 consensus, and third-quarter results also delivered an EPS beat.
- Robotics catalyst: The eCential acquisition extends the ASTRA platform into surgical robotics, with a U.S. knee launch expected around 2028.
- Valuation: A forward P/E near single digits reflects heavy impairments and loss years; better profitability could support a higher multiple.
Risks That Could Keep the Target Out of Reach
- Persistent losses: A large goodwill impairment drove trailing EPS deeply negative, with GAAP losses recurring in recent quarters.
- Margin and cash flow pressure: Robotics investments continue to weigh on near-term margins, postponing the free cash flow inflection many analysts await.
- Execution risk: Integrating eCential and delivering a U.S. robotic launch remains a multi-year effort with meaningful uncertainty.
- Wide target dispersion: The $27-to-$47 spread shows even bullish analysts differ sharply on the pace of recovery.
Technical Levels Worth Watching
The 52-week range runs from roughly $16.70 to $32.41. After the post-earnings move, the stock has reclaimed the mid-$20s zone, now acting as support near $24. Overhead resistance sits near $30 and the 52-week high near $32; a sustained break above those levels would be needed before the $36 target comes into clearer view. On the downside, the low-to-mid $20s and the $20–$21 area mark the next major support zones.
Key Items to Monitor Going Forward
Analyst targets generally look out about 12 months, though assumptions vary on margins, robotics rollout, and discount rates. Quarterly earnings, any updates to full-year guidance, free cash flow conversion metrics, eCential integration progress, and further target revisions all merit close attention. Earnings releases tend to drive most revisions here, so those dates carry extra weight.
Using AI Daily Buy/Sell Signals in My Process
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and data-driven analysis. I find these signals helpful for identifying opportunities, tracking positions, and spotting trend shifts more efficiently than manual review alone. For a name like ENOV where analyst views differ so widely, an objective signal layer adds useful perspective when filtering through each report.
Final Assessment
The $36 target averages roughly ten current analyst estimates spanning $27 to $47, pointing to about 28% upside from a recent price near $28. The bull case centers on steady organic growth, reaffirmed guidance, and the longer-term robotics opportunity, while the bear case focuses on ongoing losses, near-term margin pressure, and execution risk. The wide target range itself stands out as the clearest signal: analysts see the stock as inexpensive relative to its potential but disagree on the speed of realization. Whether ENOV reaches $36 will depend on free cash flow conversion and robotics progress over the coming quarters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ENOV in upward trend: 10-day moving average broke above 50-day moving average on October 27, 2026
The 10-day moving average for ENOV crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ENOV as a result. In 55 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
ENOV moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +37.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENOV advanced for three days, in 154 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 100 of 182 cases where ENOV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
ENOV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ENOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.117) is normal, around the industry mean (4.115). P/E Ratio (-1.483) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.466) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of fluid handling and industrial positioning products
Industry MedicalNursingServices
Advertisement